This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): REN-850
Description: REN-850 acts by inhibiting leukocyte trafficking and preclinical studies have shown that REN-850 modulates the cell migration driven by multiplechemokine receptors.
Deal Structure: This compound was originally developed by Renovis. In September 2007, Evotec AG and Renovis announced that they have entered into a definitive agreement under which Evotec will acquire Renovis. This acquisition was closed in May 2008.
Pink Sheet Weekly Trademark Review Dec. 6, 2016
Pink Sheet Weekly Trademark Review July 19, 2016
Additional information available to subscribers only: